S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
NASDAQ:BLRX

BioLineRx - BLRX Competitors

$0.76
+0.02 (+2.70%)
(As of 03/22/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.70
$0.80
50-Day Range
$0.56
$0.74
52-Week Range
$0.55
$1.98
Volume
864,376 shs
Average Volume
235,586 shs
Market Capitalization
$46.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

BLRX vs. LTRN, BYSI, SPRO, MGTA, HCWB, NXTC, NRXP, BCEL, SNSE, and LFVN

Should you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Lantern Pharma (LTRN), BeyondSpring (BYSI), Spero Therapeutics (SPRO), Magenta Therapeutics (MGTA), HCW Biologics (HCWB), NextCure (NXTC), NRx Pharmaceuticals (NRXP), Atreca (BCEL), Sensei Biotherapeutics (SNSE), and LifeVantage (LFVN). These companies are all part of the "pharmaceutical preparations" industry.

BioLineRx vs.

BioLineRx (NASDAQ:BLRX) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, community ranking and media sentiment.

BioLineRx received 485 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 85.71% of users gave Lantern Pharma an outperform vote while only 74.07% of users gave BioLineRx an outperform vote.

CompanyUnderperformOutperform
BioLineRxOutperform Votes
497
74.07%
Underperform Votes
174
25.93%
Lantern PharmaOutperform Votes
12
85.71%
Underperform Votes
2
14.29%

BioLineRx has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

In the previous week, Lantern Pharma had 8 more articles in the media than BioLineRx. MarketBeat recorded 11 mentions for Lantern Pharma and 3 mentions for BioLineRx. Lantern Pharma's average media sentiment score of 0.35 beat BioLineRx's score of 0.08 indicating that Lantern Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioLineRx
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lantern Pharma
2 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

BioLineRx presently has a consensus price target of $6.00, indicating a potential upside of 689.47%. Lantern Pharma has a consensus price target of $11.00, indicating a potential upside of 154.04%. Given BioLineRx's higher probable upside, equities research analysts plainly believe BioLineRx is more favorable than Lantern Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLineRx
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Lantern Pharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Lantern Pharma is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLineRxN/AN/A-$27.05 million-$0.49-1.55
Lantern PharmaN/AN/A-$12.36 million-$1.31-3.31

18.2% of BioLineRx shares are held by institutional investors. Comparatively, 21.6% of Lantern Pharma shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Comparatively, 23.0% of Lantern Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lantern Pharma's return on equity of -23.07% beat BioLineRx's return on equity.

Company Net Margins Return on Equity Return on Assets
BioLineRx N/A -38.63% -30.78%
Lantern Pharma N/A -23.07% -21.72%

Summary

Lantern Pharma beats BioLineRx on 9 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BLRX vs. The Competition

MetricBioLineRxPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$38.76M$5.53B$4.34B$5.82B
Dividend YieldN/A2.60%2.39%4.45%
P/E Ratio-1.553.4088.3711.27
Price / SalesN/A293.483,582.7057.27
Price / CashN/A19.3626.80101.17
Price / Book0.534.114.454.94
Net Income-$27.05M$187.02M$115.21M$190.76M
7 Day Performance24.75%-3.81%-2.49%-1.39%
1 Month Performance31.01%-10.67%-6.58%-6.86%
1 Year Performance-51.90%-14.85%-16.12%-18.39%

BioLineRx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LTRN
Lantern Pharma
2.1418 of 5 stars
$4.33
-1.6%
$11.00
+154.0%
-37.5%$47.02MN/A-3.3114Earnings Report
Analyst Report
News Coverage
BYSI
BeyondSpring
1.2587 of 5 stars
$1.18
-2.5%
$4.00
+239.0%
-49.4%$45.94M$1.35M-0.7291
SPRO
Spero Therapeutics
2.2698 of 5 stars
$1.36
-2.9%
$6.33
+365.7%
-84.3%$47.70M$18.26M-0.44146Upcoming Earnings
MGTA
Magenta Therapeutics
2.6606 of 5 stars
$0.75
flat
$4.33
+477.8%
-77.9%$45.42MN/A-0.5975Upcoming Earnings
HCWB
HCW Biologics
2.1095 of 5 stars
$1.35
+4.7%
$6.00
+344.4%
-34.1%$48.42M$4.10M0.0044
NXTC
NextCure
2.2094 of 5 stars
$1.62
-4.7%
$7.00
+332.1%
-68.4%$44.99M$22.38M-0.6087
NRXP
NRx Pharmaceuticals
1.9175 of 5 stars
$0.72
+5.9%
$3.00
+316.7%
-75.6%$48.74MN/A-1.312Upcoming Earnings
BCEL
Atreca
2.0005 of 5 stars
$1.25
-2.3%
$12.00
+860.0%
-63.0%$48.84MN/A-0.45134
SNSE
Sensei Biotherapeutics
2.1469 of 5 stars
$1.45
+2.1%
N/A-45.9%$44.54MN/A-0.9956
LFVN
LifeVantage
1.2358 of 5 stars
$3.50
+0.9%
N/A-31.1%$44.52M$206.36M-70.00263Analyst Report
News Coverage
This page (NASDAQ:BLRX) was last updated on 3/23/2023 by MarketBeat.com Staff